Talazoparib

TargetMol
Product Code: TAR-T6253
Supplier: TargetMol
CodeSizePrice
TAR-T6253-2mg2mg£99.00
Special offer! Add £1 to your order to get a TargetMol CCK-8 Kit. Read more here.
Quantity:
TAR-T6253-5mg5mg£117.00
Special offer! Add £1 to your order to get a TargetMol CCK-8 Kit. Read more here.
Quantity:
TAR-T6253-1mL1 mL * 10 mM (in DMSO)£122.00
Special offer! Add £1 to your order to get a TargetMol CCK-8 Kit. Read more here.
Quantity:
TAR-T6253-10mg10mg£137.00
Special offer! Add £1 to your order to get a TargetMol CCK-8 Kit. Read more here.
Quantity:
TAR-T6253-25mg25mg£181.00
Special offer! Add £1 to your order to get a TargetMol CCK-8 Kit. Read more here.
Quantity:
TAR-T6253-50mg50mg£229.00
Special offer! Add £1 to your order to get a TargetMol CCK-8 Kit. Read more here.
Quantity:
TAR-T6253-100mg100mg£335.00
Special offer! Add £1 to your order to get a TargetMol CCK-8 Kit. Read more here.
Quantity:
TAR-T6253-200mg200mg£434.00
Special offer! Add £1 to your order to get a TargetMol CCK-8 Kit. Read more here.
Quantity:
Prices exclude any Taxes / VAT

Overview

Regulatory Status: RUO
Shipping:
cool pack
Storage:
-20℃

Images

1 / 1

Further Information

Bioactivity:
Talazoparib is a new-type PARP inhibitor (IC50: 0.58 nM), It similarly binds to PARP1/2 (Kis: 1.2/0.85 nM).
CAS:
1207456-01-6
Formula:
C19H14F2N6O
Molecular Weight:
380.359
Pathway:
DNA Damage/DNA Repair; Chromatin/Epigenetic
Purity:
0.9982
SMILES:
Cn1ncnc1[C@@H]1[C@H](N=c2cc(F)cc3C(=O)NNC1=c23)c1ccc(F)cc1
Target:
PARP

References

Shen YQ, et al. Cancer Research, 2010, 70 (8 Suppl), Abstract nr 3514. Kiehlmeier S, Rafiee M R, Bakr A, et al. Identification of therapeutic targets of the hijacked super-enhancer complex in EVI1-rearranged leukemia[J]. Leukemia. 2021: 1-12. Hou X, Tian M, Ning J, et al.PARP inhibitor shuts down the global translation of thyroid cancer through promoting Pol II binding to DIMT1 pause.International Journal of Biological Sciences.2023, 19(12): 3970. Wang B, et al. Molecular Cancer Therapeutics, 2009, 8 (12 Suppl), A121. Kiehlmeier S, Rafiee M R, Bakr A, et al. Identification of therapeutic targets of the hijacked super-enhancer complex in EVI1-rearranged leukemia. Leukemia. 2021 Nov;35(11):3127-3138. doi: 10.1038/s41375-021-01235-z. Epub 2021 Apr 28. Mateos-Pujante A, Jim?nez M C, Andreu I.Assessment of the PARP inhibitor talazoparib photosafety profile.Biomedicine & Pharmacotherapy.2023, 167: 115593. Kamaletdinova T, Zong W, Urb?nek P, et al.Poly (ADP-Ribose) Polymerase-1 Lacking Enzymatic Activity Is Not Compatible with Mouse Development.Cells.2023, 12(16): 2078.